National Eczema Association Publishes First Comprehensive National and State-Level Report on Atopic Dermatitis

The CDC-funded National Eczema Association report estimates that only 6.9 million insured Americans had diagnosed atopic dermatitis in 2023—roughly one-fifth of the estimated affected population—highlighting substantial underdiagnosis. Access gaps are material, with 13% of Americans living in counties without dermatology or allergy/immunology practitioners, while guideline-recommended biologics reach only 2%-4% of diagnosed patients. The findings point to unmet need and potential for expanded diagnosis and advanced-treatment adoption, but are unlikely to materially move public markets immediately.

Analysis

This is not an immediate earnings catalyst; it is a reimbursement-and-diagnosis funnel data point. The investable implication is a larger addressable pool for systemic AD therapies, but conversion depends on primary-care screening, referral capacity and payer step-therapy rules rather than patient awareness alone. In the next 12-24 months, the most direct beneficiaries are Regeneron/Sanofi's Dupixent franchise (REGN, SNY) and AbbVie's Rinvoq (ABBV), while Incyte (INCY) can benefit at the milder end through topical Opzelura adoption; however, the report itself provides no evidence that prescribing behavior is changing yet.

The non-obvious constraint is specialist scarcity: it may favor drugs with established primary-care familiarity and low administrative friction over newer or more complex alternatives. Dupixent's broad atopic-disease footprint can create cross-specialty referral and persistence advantages where asthma co-management is common, supporting share durability despite premium pricing. Conversely, expanded diagnosis without meaningful specialist access could first increase inexpensive topical and steroid utilization, limiting near-term systemic conversion and potentially raising medical-loss-ratio pressure for Medicaid-heavy managed-care plans.

Consensus likely already capitalizes Dupixent as a mature growth asset, so broad prevalence estimates alone should not justify chasing REGN. The higher-value signal would be evidence over the next 1-3 months that insurers relax prior authorization, primary-care systems add AD screening pathways, or state Medicaid formularies improve biologic access. Over 6-18 months, treatment adoption could also expand the commercial opportunity for AD pipeline entrants, increasing competitive risk to incumbent net pricing before materially changing total treated patients.

Key Decisions for Investors

• No event-driven position on this release alone; monitor October payer-policy updates and the next REGN/SNY and ABBV earnings calls for AD new-start growth, gross-to-net commentary and primary-care channel expansion.
• Maintain a 6-12 month quality bias toward REGN versus ABBV for AD exposure if Dupixent patient growth remains above consensus while net price holds; reassess if U.S. Dupixent growth decelerates materially or Rinvoq AD share gains accelerate.
• Use INCY as a watch item rather than a recommendation: initiate only if Opzelura prescription growth improves alongside evidence of earlier diagnosis, since broad underdiagnosis is more likely to initially expand topical treatment than systemic biologic use.
• For managed care, monitor UNH, ELV and CVS/Aetna Medicaid utilization trends. A rise in biologic approvals without offsetting reductions in emergency visits or steroid complications would be a 12-24 month margin headwind, but the current data do not establish that utilization inflection.